UTHRUnited Therapeutics Corporation

$24B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$492M+18.4% YoY

Gross Profit

$436M88.6% margin

Operating Income

$176M35.7% margin

Net Income

$132M26.9% margin

EPS (Diluted)

$2.67

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

$128M

Free Cash Flow

$89M

Stock-Based Comp.

$65M

Balance Sheet

Total Assets

$6.0B

Total Liabilities

$1.2B

Stockholders' Equity

$4.8B

Cash & Equivalents

$961M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$492M	$415M	+18.4%
Gross Profit	$436M	$381M	+14.5%
Operating Income	$176M	$170M	+3.4%
Net Income	$132M	$112M	+17.7%

Revenue Segments

Tyvaso

$242M49%

Remodulin

$123M25%

Orenitram

$76M15%

Unituxin

$37M7%

Adcirca

$10M2%

Product and Service, Other

$4M1%

Geographic Segments

UNITED STATES

$464M94%

Non-US

$28M6%

UTHR Q4 2022 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena